Department of Pharmacology and Toxicology - Institute of Pharmacy

• Medical and Pharmacy students
  • seminars / lectures in pharmacology, toxicology, clinical pharmacy and pharmacology
  • small group teaching in pharmacology and toxicology
  • physiology and pathophysiology for pharmacy students
• School of Nursing
  • lectures in pharmacology and toxicology
• Graduate program "Molecular Cell Biology"
  • lectures and seminars on "signal transduction, receptors and electrical excitability"
• Continuing education of pharmacists and physicians
  • lectures and seminars on clinical pharmacology and drug therapy

• Science award of the Ärztekammern für Tirol und Vorarlberg (1988)
• Award of a Max-Kade Fellowship from the Austrian Academy of Sciences (1989 - 1991)
• Science award from the City of Innsbruck (1992, 2002)
• International Albrecht Fleckenstein Award (2000)
• Co - awardee on awards for young members of the research group (HOECHST awards 1997, 1998, 2000)
• Wulf - Vater Dihydropyridine - award (1998)
• Research Award for Scientific Excellence (Innsbruck Universities, 2011)
• Tyrolean Research Award 2012
  
• Phoenix Award in Pharmaceutical Sciences (Pharmacology and Clinical Pharmacology, 2015)
  

Numer of citrations: 17,014 without self citations (Web of Science)

h - Index: 72

148 original publications, 24 reviews articles (with peer review)

Striessnig J, Murphy BJ, Catterall WA (1991)
"The dihydropyridine receptor of L-type Ca2+ channels: Identification of binding domains for (+)-[3H]PN200-110 and [3H]azidopine within the α1 subunit"
Proc Natl Acad Sci (USA): 88: 10769-10773

Kraus RL, Sinnegger MJ, Glossmann H, Hering S, Striessnig J (1998)
"Familial hemiplegic migraine mutations change α1A Ca2+ channel kinetics"
J Biol Chem: 273: 5586-5590

Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H (1998)
"Structural basis of drug binding to L-type Ca2+ channels"
Trends Pharmacol Sci: 19: 108-115

Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J (2000)
"Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels"
Cell: 102: 89-97

Koschak A, Reimer D, Huber IG, Grabner M, Glossmann H, Engel J, Striessnig J (2001)
"α1D (Cav1.3) subunits can form L-type Ca2+ channels activating at negative voltages"
J Biol Chem: 276: 22100-22106

Pietrobon D, Striessnig J (2003)
"Neurobiology of migraine"
Nature Rev Neurosci: 4: 386-398

Koschak A, Reimer D, Walter D, Hoda J-C, Heinzle T, Grabner M, Striessnig J (2003)
"Cav1.4α1 subunits can form slowly inactivating dihydropyridine - sensitive L-type Ca2+ channels lacking Ca2+ - dependent inactivation"
J Neurosci: 23: 6041-6049

Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renström E, Wietzorrek G, Berjukov S, Cavalli M, Walter D, Koschak A, Waldschütz R, Hering S, Bova S, Rorsman P, Pongs O, Singewald S, Striessnig J (2004)
"Cav1.3 L-type Ca2+-channels: Role for isoform-specific regulation of mood behavior, pancreatic β - cell and cardiovascular function"
J Clin Invest: 113: 1430-1439

Singh A, Hamedinger D, Hoda JC, Gebhart M, Koschak A, Romanin C, Striessnig J (2006)
"C-terminal modulator controls Ca2+-dependent gating of Cav 1.4 L-type calcium channels"
Nature Neurosci: 9: 1108-1116

Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I, Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P, Striessnig J, Bolz HJ (2011)
"Loss of Cav1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness"
Nature Neurosci: 14: 77-84

Bock G, Gebhart M, Scharinger A, Jangsangthong W, Busquet P, Poggiani C, Sartori S, Mangoni ME, Sinnegger-Brauns MJ, Herzig S, Striessnig J, Koschak A (2011)
"Functional Properties of a Newly Identified C-terminal Splice Variant of Cav1.3 L-type Ca2+ Channels."
J Biol Chem 286:42736-48

Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ (2013)
"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension."
Nat Genet 45:1055-60

Ortner N, Bock G, Vandael DH, Mauersberger R, Draheim HJ, Gust R, Carbone E, Tuluc P Striessnig J (2014)
"Pyrimidine 2, 4, 6-triones are a new class of voltage-gated L-type calcium channel activators."
Nat Commun, Jun 19;5:3897. doi: 10.1038/ncomms4897

Pinggera A, Lieb A, Benedetti B, lampert M, Monteleone S, Liedl KR, Tuluc P, Striessnig J (2015)
CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type Ca2+ channels.
Biol Psychiatry 77: 816-822

Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015)
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.
Pharmacol. Rev. 67, 821–870

Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc T, Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim HJ, Kloppenburg P, Liss B, Striessnig J (2017)
Lower Affinity of Isradipine for L-Type Ca²⁺ Channels during Substantia Nigra Dopamine Neuron-like Activity: Implications for Neuroprotection in Parkinson’s Disease.
J Neurosci 37: 6761-6777

Benkert J, Hess S, Roy S, Beccano-Kelly D, Wiederspohn N, Duda J, Simons C, Patil K, Gaifullina A, Mannal N, Dragicevic E, Spaich D, Müller S, Nemeth J, Hollmann H, Deuter N, Mousba Y, Kubisch C, Poetschke C, Striessnig J, Pongs O, Schneider T, Wade-Martins R, Patel S, Parlato R, Frank T, Kloppenburg P, Liss B (2019)
Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease.
 Nat Commun 10:5094.

Hofer NT, Tuluc P, Ortner NJ, Nikonishyna YV, Fernándes-Quintero ML, Liedl KR, Flucher BE, Cox H, Striessnig J (2019)
Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder.
Mol Autism 11:4

Liss B, Striessnig J (2019)
The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson’s Disease.
Annu Rev Pharmacol Toxicol 59: 263-289

Ortner NJ, Kaserer T, Copeland JN, Striessnig J (2020)
De novo CACNA1D Ca2+ channelopathies: clinical phenotypes and molecular mechanism.
Pflugers Arch 472:755-773

Striessnig J (2021)
Voltage-Gated Ca²⁺-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies (Front Synaptic Neurosci 13:634760